Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Sees Significant Decline in Short Interest

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the recipient of a large drop in short interest in May. As of May 29th, there was short interest totaling 33,421 shares, a drop of 58.4% from the May 14th total of 80,248 shares. Based on an average trading volume of 57,636 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.1% of the company’s stock are short sold.

Nanobiotix Stock Up 0.6%

NBTX stock traded up $0.21 during trading on Friday, reaching $35.54. 84,271 shares of the company were exchanged, compared to its average volume of 57,193. Nanobiotix has a 52-week low of $4.18 and a 52-week high of $57.14. The stock’s 50 day moving average price is $37.63 and its 200 day moving average price is $29.41.

Nanobiotix (NASDAQ:NBTX) last announced its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $3.42 million for the quarter. On average, research analysts expect that Nanobiotix will post 0.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NBTX has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th. UBS Group upped their price objective on Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. Guggenheim boosted their price target on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. Finally, TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.33.

Hedge Funds Weigh In On Nanobiotix

Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada lifted its stake in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the period. Optiver Holding B.V. purchased a new position in shares of Nanobiotix during the third quarter valued at approximately $101,000. Marshall Wace LLP acquired a new stake in shares of Nanobiotix in the fourth quarter worth approximately $220,000. Finally, Millennium Management LLC acquired a new stake in shares of Nanobiotix in the fourth quarter worth approximately $390,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.